Advances in Clinical Medicine
Vol. 13  No. 08 ( 2023 ), Article ID: 70609 , 6 pages
10.12677/ACM.2023.1381787

儿童急性淋巴细胞白血病诱导化疗期间合并可逆性后部脑2例并文献复习

徐彤1*,仲任2,姜红1#

1青岛大学附属医院新生儿科,山东 青岛

2青岛大学附属医院儿童血液肿瘤科,山东 青岛

收稿日期:2023年7月13日;录用日期:2023年8月8日;发布日期:2023年8月15日

摘要

目的:可逆性后部脑(posterior reversible encephalopathy syndrome, PRES)是急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)治疗过程中的一种并发症,重点探讨该病可能的诱发因素及发病机制,临床上尽可能避免该病的发生。方法:回顾性分析2例ALL合并PRES患儿的临床、影像学资料、治疗及预后转归,并结合文献复习。结果:两例病例皆是在诱导化疗期间长春新碱(vincristine, VCR)联合泊沙康唑应用后发生PRES,同时伴有化疗期间感染及多次输血,预后都较好。结论:ALL化疗期间需严格把握输血指征,及时控制感染,规范使用丙种球蛋白及粒细胞集落刺激因子,尽量避免在使用VCR期间合用泊沙康唑,如必须使用,应关注血脂水平及便秘问题。

关键词

可逆性后部脑,急性淋巴细胞白血病,诱发因素,儿童

Encephalopathy Syndrome in Children with Acute Lymphoblastic Leukemia after Induction Chemotherapy: 2 Cases Report and Literature Review

Tong Xu1*, Ren Zhong2, Hong Jiang1#

1Neonate Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao Shandong

2Hematology and Oncology Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao Shandong

Received: Jul. 13th, 2023; accepted: Aug. 8th, 2023; published: Aug. 15th, 2023

ABSTRACT

Objective: Posterior reversible encephalopathy syndrome (PRES) is a complication in treating acute lymphoblastic leukaemia (ALL). The focus was on the possible predisposing factors and pathogenesis of the disease and to avoid the occurrence of the disease in clinical practice. Methods: Summarize and analyze the clinical data of 2 cases of ALL combined with PRES and review relevant literature. Results: In both cases, PRES occurred after induction chemotherapy with vincristine (VCR) combined with posaconazole, accompanied by infection during chemotherapy and multiple blood transfusions, and the prognosis was improved. Conclusion: Strict control of blood transfusion indications during ALL chemotherapy, timely control of infection, standardised use of gammaglobulin and granulocyte colony-stimulating factor, and avoiding the use of posaconazole in combination with VCR as much as possible, and if necessary, paying attention to lipid levels and constipation.

Keywords:Posterior Reversible Encephalopathy Syndrome, Acute Lymssphoblastic Leukaemia, Predisposing Factors, Children

Copyright © 2023 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 引言

可逆性后部脑(posterior reversible encephalopathy syndrome, PRES)是一种(亚)急性发作的神经系统疾病,其特征是各种神经系统症状,可能包括头痛、视力受损或视野缺损、意识障碍、意识模糊、癫痫发作和局灶性神经功能缺损。急性淋巴细胞性白血病(acute lymphoblastic leukemia, ALL)患者在诱导化疗期间经常发生PRES,但在造血干细胞移植和维持化疗期间也可能发生PRES [1] [2] [3] 。现报道2例ALL患者在诱导化疗期间发生PRES的患者资料。

2. 病例资料

病例1,患儿,男,6岁。因“间断发热10天”于2022年05月08日入院。入院查体:全身皮肤散在陈旧性皮疹,压之褪色,颈部可触及多枚淋巴结,咽稍红,背部散在出血点。辅助检查:骨髓常规:增生极度活跃,原始 + 幼稚淋巴细胞比例约占92.0%。诊断:ALL (低危)。按照CCCG-ALL-2020低危方案化疗,同时予哌拉西林钠他唑巴坦抗感染治疗,输注红细胞、冰冻血浆及丙种球蛋白支持治疗,泊沙康唑预防真菌感染,在VDLD化疗期间第3次长春新碱应用(2022年05月29号)后患儿出现腹痛,脐周为主,伴腹胀,食欲差,患儿胃管内引流出暗红色血性液体,考虑麻痹性肠梗阻可能,予禁饮食,静脉营养治疗,同时留置胃管,持续胃肠减压,粒细胞刺激因子升白,2022年6月1号患儿出现一过性升级抗生素为美罗培南抗感染治疗。2022年06月04号患儿出现无热抽搐,主要表现为:双眼紧闭,头部抖动,双手紧握,四肢稍抖动,意识丧失,无大小便失禁,无口唇青紫,无恶心、呕吐,持续约5分钟后自行缓解。后患儿当日再次出现抽搐2次,分别静推安定6 mg及力月西4 mg后缓解。查体:血压125/83 mmHg,神志清,精神差。全身皮肤无花纹,颈部稍抵抗。双眼对光反射灵敏,口唇略苍白。四肢肌张力正常,脑膜刺激征阴性,右侧巴氏征弱阳性,左侧阴性。心腹查体未见异常。辅助检查:电解质:钠122.9 mmol/L,氯89.2 mmol/L,钾3.31 mmol/L;血糖:葡萄糖3.80 mmol/L;颅脑MR:双侧颞枕叶皮层部、右侧丘脑flair、DWI高信号影;24小时视频脑电监测提示右侧枕颞叶尖慢波。诊断考虑PRES可能。治疗与随访:立即予甘露醇降颅压、甲强龙减轻炎症反应,予丙戊酸钠、苯巴比妥预防及治疗抽搐。后患儿逐渐好转,神志清,未再见抽搐,神经系统检查未见异常。2022年06月21号继续使用CCCG-ALL-2020方案治疗,予CAT方案化疗,监测颅脑MR病灶逐渐吸收好转。

病例2,患儿男,7岁,因“发热伴血象异常2天”于2022年04月03日入院。入院查体:神志清,精神可。面色及口唇苍白,全身散在针尖大小出血点,腹软,无压痛及反跳痛,肝脏肋下3 cm,脾脏肋下2 cm,肠鸣音存在,心肺查体未见异常。辅助检查:骨髓常规:增生明显活跃,原始 + 幼稚淋巴细胞比例约占94.5%。诊断:ALL (中危)。按照CCCG-2020-ALL-中危诱导缓解,ALL-I/HR诱导缓解(1~4周),考虑患儿存在感染情况,4.03予以头孢曲松钠静滴10天。患儿血红蛋白及血小板低,定期监测血象,多次予合血输血治疗,泊沙康唑预防真菌感染。4.18患儿体温仍有增高,抗生素改为哌拉西林钠他唑巴坦钠。2022年04月23号出现抽搐,表现为:意识丧失,呼之不应,双眼向右上凝视,面色、口唇发绀,四肢抖动。2022年04月24号患儿出现视物模糊,眼底镜检查未见眼底出血,2022年04月28号患儿再次出现抽搐1次,发作形式同前类似。查体:体温正常,双侧瞳孔直径约4 mm,等大等圆,对光反射灵敏。呼吸35次/分,双肺可闻及痰鸣音。心率150~155次/分,心律齐,各瓣膜听诊区未闻及杂音。立即予持续心电监护、面罩吸氧3 L/min,予水合氯醛、地西泮、力月西止惊后患儿抽搐停止。辅助检查:钠132.6 mmol/L,尿素9.89 mmol/L,补体C1q 145.80 mg/L,磷1.54 mmol/L,载脂蛋白A1 1.65 g/L,总胆固醇6.32 mmol/L,低密度脂蛋白胆固醇3.74 mmol/L,血钙2.09 mmol/L,血镁0.87 mmol/L。颅脑MR:双侧枕叶、顶叶及双侧额叶见片状长T1、长T2信号,T2flair上为高信号,DWI为部分高信号,部分低信号,双侧枕叶病灶内夹杂点状DWI低信号,病灶以皮质受累为著。双侧额顶枕部皮层改。诊断考虑PRES可能。治疗与随访:予甘露醇降颅压、丙戊酸钠抗癫痫,美罗培南抗感染,氟康唑预防真菌感染,温盐水灌肠。2022年05月17患儿出现眼睛左斜视,完善脑电图监测到数次右侧枕区起始局灶性发作,发作间期双侧枕区尖形慢波发放。丙戊酸钠加量至一次7 ml Q8h。患儿左眼斜视逐渐减轻,未再见抽搐发作,2022年05月19号继续按照CCCG-2020-ALL中危化疗,予CTX + Rrac + 6MP化疗,监测颅脑MR病灶逐渐吸收好转。

3. 讨论

3.1. 临床表现

表现为神经系统症状的急性发作。癫痫发作和头痛是最常见的症状。其他常见症状包括视力障碍、精神状态改变、轻偏瘫、失语、共济失调和其他局灶性缺陷。一项回顾性研究纳入了151例PRES患者,发现66%的患者出现癫痫发作,30%的患者出现视力障碍,40%的患者出现精神状态改变,12%的患者出现麻痹 [4] 。

3.2. 诱发因素

在接受化疗的白血病患者中,已确定了几个发生PRES的危险因素和病因,包括高血压 [5] [6] [7] ,化疗细胞毒性 [8] [9] ,肿瘤溶解综合征,移植物抗宿主病,感染,全身炎症反应综合征 [10] ,败血症,免疫抑制治疗 [5] [11] [12] 。其次,化疗期间可能用到的促红细胞生成素、粒细胞集落刺激因子、免疫球蛋白、输血等也是PRES的高危因素 [13] 。急性淋巴细胞白血病化疗方案,包括全身类固醇、重复鞘内注射甲氨蝶呤、左旋门冬酰胺酶和长春新碱(Vincristine, VCR),是诱导化疗期间并发后可逆性脑病综合征的主要诱发因素 [8] 。同时包括泊沙康唑在内的唑类药物与VCR联合给药会导致VCR毒性增加,VCR由细胞色素P4503A (CYP3A)亚家族代谢 [14] ,唑类药物(酮康唑、伊曲康唑、伏立康唑、氟康唑和泊沙康唑)通过CYP3A抑制VCR的代谢,泊沙康唑是肝脏中一种有效的CYP3A抑制剂 [15] ,当与CYP3A底物(VCR)一起给药时,VCR的血浆浓度可能会增加到中毒水平。泊沙康唑主要从粪便中排出 [16] ,高脂血症会导致泊沙康唑的药代动力学和组织分布的显着变化。脂蛋白升高下的泊沙康唑和VCR的联合给药,会进一步导致泊沙康唑组织分布的进一步延迟,同时它导致VCR组织摄取和浓度增加 [17] 。两例病例皆是在诱导化疗期间VCR联合泊沙康唑应用后发生PRES,同时伴有化疗期间感染及多次输血,病例一发病期间伴有麻痹性肠梗阻,病例二伴有低密度脂蛋白的升高,进一步影响VCR的代谢,除此之外,病例一还有免疫球蛋白及粒细胞集落刺激因子的应用。

3.3. 发病机制

PRES的发病机制有多种理论 [18] :第一种理论为“血管源性理论”,认为动脉血压迅速升高到高血压危象或急症 [19] ;第二种理论为“细胞毒性理论”,认为外源性毒素和化学物质可能对脑血管内皮产生直接毒性,导致血脑屏障破坏 [20] ;第三种理论为“免疫原性理论”,认为由于T细胞活化和细胞因子或血管活性物质如组胺和一氧化氮的释放可能引起内皮细胞损坏 [21] [22] ;第四种理论为“神经肽/脑血管收缩理论”,认为内皮素1和血栓素A2等介质释放引起的严重脑血管收缩可能导致内皮功能障碍并导致水肿 [21] [22] 。理论各不相同,但都有共同的关键病理生理改变,包括内皮的激活和损伤、免疫系统的激活和相关细胞因子的释放 [23] ,伴随着随后的包括大脑在内的多个器官系统的低灌流、血管自身调节异常、血脑屏障的破坏和局部的血管源性水肿 [24] 。该病例中所用的VCR等化疗药物可能通过这种机制诱发PRES。

3.4. 影像学

MRI是诊断PRES的主要影像学检查方法,PRES的典型影像表现在FLAIR图像上表现为顶枕叶和额叶后部皮质及皮质下白质的高信号,少见累及脑干、基底节和小脑。在急性期的CT扫描中,典型的PRES的影像表现为低密度区,主要位于枕叶和顶叶的白质周围,MRI中主要表现为在增强的T2加权图像上表现为低信号到等信号,在FLAIR图像上变得更加明显。三项回顾性队列研究发现PRES患者脑脊液蛋白水平升高而无脑脊液细胞增多,这被称为“白蛋白–细胞学分离” [25] [26] [27] 。在两项研究中,血管源性水肿的放射学严重程度与脑脊液总蛋白水平呈正相关 [26] [27] 。

3.5. 预后

PRES的神经症状和放射学异常表现通常在治疗后几天至几周内消失,特别是在及时诊断和治疗的患者 [20] [28] 。然而,在某些情况下,可能会出现脑出血、脑梗塞、蛛网膜下腔出血等不可逆的脑损害,留下持久的神经损伤,甚至导致死亡 [13] 。

4. 结论

综上所述,在ALL化疗期间需严格把握输血指征,及时控制感染,规范使用丙种球蛋白及粒细胞集落刺激因子。根据细胞毒性理论,病例中所用化疗药物VCR通过此种机制对血管内皮直接产生毒性,导致血脑屏障破坏引起PRES,同时联合应用泊沙康唑会导致VCR的毒性增加,泊沙康唑从粪便中排出,便秘和脂蛋白水平的升高,进一步影响了泊沙康唑和长春新碱的代谢,所以,尽量避免在使用VCR期间合用泊沙康唑,如必须使用,应关注血脂水平及便秘问题。

文章引用

徐 彤,仲 任,姜 红. 儿童急性淋巴细胞白血病诱导化疗期间合并可逆性后部脑2例并文献复习
Encephalopathy Syndrome in Children with Acute Lymphoblastic Leukemia after Induction Chemotherapy: 2 Cases Report and Literature Review[J]. 临床医学进展, 2023, 13(08): 12747-12752. https://doi.org/10.12677/ACM.2023.1381787

参考文献

  1. 1. Norman, J.K., Parke, J.T., Wilson, D.A. and McNall-Knapp, R.Y. (2007) Reversible Posterior Leukoencephalopathy Syndrome in Children Undergoing Induction Therapy for Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer, 49, 198-203. https://doi.org/10.1002/pbc.20597

  2. 2. Gupta, A., Swaroop, C., Rastogi, R., Garg, R. and Bakhshi, S. (2008) Simultaneous Occurrence of Posterior Reversible Leukoencephalopathy Syndrome in Two Cases of Childhood Acute Lymphoblastic Leukemia Induction Chemotherapy. Pediatric Hematology and Oncology, 25, 351-358. https://doi.org/10.1080/08880010802016052

  3. 3. Morris, E.B., Laningham, F.H., Sandlund, J.T. and Khan, R.B. (2007) Posterior Reversible Encephalopathy Syndrome in Children with Cancer. Pediatric Blood & Cancer, 48, 152-159. https://doi.org/10.1002/pbc.20703

  4. 4. Siebert, E., Bohner, G., Liebig, T., Endres, M. and Liman, T.G. (2017) Factors Associated with Fatal Outcome in Posterior Reversible Encephalopathy Syndrome: A Retrospective Analysis of the Berlin PRES Study. Journal of Neurology, 264, 237-242. https://doi.org/10.1007/s00415-016-8328-4

  5. 5. Hinchey, J., Chaves, C., Appignani, B., Breen, J., Pao, L., Wang, A., Pessin, M.S., Lamy, C., Mas, J.L. and Caplan, L.R. (1996) A Reversible Posterior Leukoencephalopathy Syndrome. The New England Journal of Medicine, 334, 494-500. https://doi.org/10.1056/NEJM199602223340803

  6. 6. Millichap, J.G. (2015) Posterior Reversible Encephalopathy Syndrome in ALL. Pediatric Neurology Briefs, 29, Article 56.

  7. 7. Kanekiyo, T., Hara, J., Matsuda-Hashii, Y., Fujisaki, H., Tokimasa, S., Sawada, A., Kubota, K., Shimono, K., Imai, K. and Ozono, K. (2005) Tacrolimus-Related Encephalo-pathy following Allogeneic Stem Cell Transplantation in Children. International Journal of Hematology, 81, 264-268. https://doi.org/10.1532/IJH97.04162

  8. 8. Kim, S.J., Im, S.A., Lee, J.W., Chung, N.G., Cho, B., Kim, H.K. and Lee, I.G. (2012) Predisposing Factors of Posterior Reversible Encephalopathy Syndrome in Acute Childhood Leukemia. Pediatric Neurology, 47, 436-442. https://doi.org/10.1016/j.pediatrneurol.2012.07.011

  9. 9. Panis, B., Vlaar, A.M., van Well, G.T., Granzen, B., We-ber, J.W., Postma, A.A. and Klinkenberg, S. (2010) Posterior Reversible Encephalopathy Syndrome in Paediatric Leu-kaemia. European Journal of Pediatric Neurology, 14, 539-545. https://doi.org/10.1016/j.ejpn.2010.01.003

  10. 10. Bartynski, W.S., Tan, H.P., Boardman, J.F., Shapiro, R. and Marsh, J.W. (2008) Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation. American Journal of Neuroradiology, 29, 924-930. https://doi.org/10.3174/ajnr.A0960

  11. 11. Bartynski, W.S., Zeigler, Z., Spearman, M.P., Lin, L., Shadduck, R.K. and Lister, J. (2001) Etiology of Cortical and White Matter Lesions in Cyclosporin-A and FK-506 Neurotoxicity. American Journal of Neuroradiology, 22, 1901-1914.

  12. 12. Reinohs, M., Straube, T., Baum, P., Berrouschot, J. and Wagner, A. (2002) Recurrent Reversible Cerebral Edema after Long Term Immunosuppression with Tacrolimus. Journal of Neurol-ogy, 249, 780-781. https://doi.org/10.1007/s00415-002-0703-7

  13. 13. Tetsuka, S. and Ogawa, T. (2019) Posterior Reversible Encepha-lopathy Syndrome: A Review with Emphasis on Neuroimaging Characteristics. Journal of the Neurological Sciences, 404, 72-79. https://doi.org/10.1016/j.jns.2019.07.018

  14. 14. Chan, J.D. (1998) Pharmacokinetic Drug Interactions of Vinca Alkaloids: Summary of Case Reports. Pharmacotherapy, 18, 1304-1307.

  15. 15. Li, Y., Theuretzbacher, U., Clancy, C.J., Nguyen, M.H. and Derendorf, H. (2010) Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics, 49, 379-396. https://doi.org/10.2165/11319340-000000000-00000

  16. 16. Chen, L., Krekels, E.H.J., Verweij, P.E., Buil, J.B., Knibbe, C.A.J. and Brüggemann, R.J.M. (2020) Pharmacokinetics and Pharmacody-namics of Posaconazole. Drugs, 80, 671-695. https://doi.org/10.1007/s40265-020-01306-y

  17. 17. Khalil, H.A., ElKhatib, M.A.W., Belal, T.S., El-Yazbi, A.F. and Hamdy, D.A. (2017) Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine upon Co-Administration in Rats. Drugs in R & D, 17, 287-296. https://doi.org/10.1007/s40268-017-0178-8

  18. 18. Gao, B., Lyu, C., Lerner, A. and McKinney, A.M. (2018) Con-troversy of Posterior Reversible Encephalopathy Syndrome: What Have We Learnt in the Last 20 Years? Journal of Neurology, Neurosurgery, and Psychiatry, 89, 14-20. https://doi.org/10.1136/jnnp-2017-316225

  19. 19. Fugate, J.E. and Rabinstein, A.A. (2015) Posterior Reversible En-cephalopathy Syndrome: Clinical and Radiological Manifestations, Pathophysiology, and Outstanding Questions. The Lancet Neurology, 14, 914-925. https://doi.org/10.1016/S1474-4422(15)00111-8

  20. 20. Liman, T.G., Siebert, E. and Endres, M. (2019) Posterior Reversible Encephalopathy Syndrome. Current Opinion in Neurology, 32, 25-35. https://doi.org/10.1097/WCO.0000000000000640

  21. 21. Fischer, M. and Schmutzhard, E. (2017) Posterior Reversi-ble Encephalopathy Syndrome. Journal of Neurology, 264, 1608-1616. https://doi.org/10.1007/s00415-016-8377-8

  22. 22. Singer, S., Grommes, C., Reiner, A.S., Rosenblum, M.K. and DeAngelis, L.M. (2015) Posterior Reversible Encephalopathy Syndrome in Patients with Cancer. The Oncologist, 20, 806-811. https://doi.org/10.1634/theoncologist.2014-0149

  23. 23. Chen, Z., Shen, G.Q., Lerner, A. and Gao, B. (2017) Im-mune System Activation in the Pathogenesis of Posterior Reversible Encephalopathy Syndrome. Brain Research Bulletin, 131, 93-99. https://doi.org/10.1016/j.brainresbull.2017.03.012

  24. 24. Bartynski, W.S. and Boardman, J.F. (2008) Catheter Angi-ography, MR Angiography, and MR Perfusion in Posterior Reversible Encephalopathy Syndrome. American Journal of Neuroradiology, 29, 447-455. https://doi.org/10.3174/ajnr.A0839

  25. 25. Datar, S., Singh, T.D., Fugate, J.E., Mandrekar, J., Rabinstein, A.A. and Hocker, S. (2015) Albuminocytologic Dissociation in Posterior Reversible Encephalopathy Syndrome. Mayo Clinic Proceedings, 90, 1366-1371. https://doi.org/10.1016/j.mayocp.2015.07.018

  26. 26. Neeb, L., Hoekstra, J., Endres, M., Siegerink, B., Siebert, E. and Liman, T.G. (2016) Spectrum of Cerebral Spinal Fluid Findings in Patients with Posterior Reversible Encephalopa-thy Syndrome. Journal of Neurology, 263, 30-34. https://doi.org/10.1007/s00415-015-7928-8

  27. 27. Ellis, C.A., McClelland, A.C., Mohan, S., Kuo, E., Kasner, S.E., Zhang, C., Khankhanian, P. and Balu, R. (2019) Cerebrospinal Fluid in Posterior Reversible Encephalopathy Syndrome: Implications of Elevated Protein and Pleocytosis. The Neurohospitalist, 9, 58-64. https://doi.org/10.1177/1941874418802061

  28. 28. Liman, T.G., Bohner, G., Endres, M. and Siebert, E. (2014) Dis-charge Status and in-Hospital Mortality in Posterior Reversible Encephalopathy Syndrome. Acta Neurologica Scandina-vica, 130, 34-39. https://doi.org/10.1111/ane.12213

  29. NOTES

    *第一作者。

    #通讯作者。

期刊菜单